EP2229180A1 - Composition comprising superoxide dismutase and carboxv methyl beta-1,3 glucan - Google Patents

Composition comprising superoxide dismutase and carboxv methyl beta-1,3 glucan

Info

Publication number
EP2229180A1
EP2229180A1 EP07866845A EP07866845A EP2229180A1 EP 2229180 A1 EP2229180 A1 EP 2229180A1 EP 07866845 A EP07866845 A EP 07866845A EP 07866845 A EP07866845 A EP 07866845A EP 2229180 A1 EP2229180 A1 EP 2229180A1
Authority
EP
European Patent Office
Prior art keywords
composition
glucan
superoxide dismutase
methyl beta
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07866845A
Other languages
German (de)
French (fr)
Inventor
Luigi Mercuri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DMG Italia SRL
Original Assignee
DMG Italia SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DMG Italia SRL filed Critical DMG Italia SRL
Publication of EP2229180A1 publication Critical patent/EP2229180A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)

Definitions

  • composition comprising superoxide dismutase and carboxy methyl beta 1,3- glucan Description of the invention
  • the present invention refers to the pharmaceutical field and in particular to a composition comprising superoxide dismutase and carboxy methyl beta 1-3 glucan in the form of liposomes or phosphoglucan to be used in the ophthalmic field for preventing the corneal epithelium degeneration caused by aging and oxidative stress.
  • CGM carboxy methyl beta 1-3 glucan
  • CGM is preferably in aqueous solution and more preferably in a concentration from 0,2 % to 2%.
  • the pharmaceutical preparation for ophthalmic use comprises CGM 0,5%, N-hydroxymethyl glicinate 0,001%, sodium edetate 0,1% and isotonic solution pH 7,2.
  • the International patent application N. PCT/IT2006/000543 discloses a pharmaceutical preparation for ophthalmic use or for oral administration comprising sodium carboxymethyl-beta-1,3- glucan CGM inside liposomes or bound to the liposome membrane, able to improve the lubrication of the eye and to protect the eye from irritation.
  • the complex between sodium CGM and liposomes is preferably in a concentration from 0,1% to 50%, more preferably from 0,1 % to 5%.
  • the same application discloses a cosmetic composition, comprising the same sodium CGM/liposomes complex, with a protective and regenerative effect on the skin.
  • CGM/liposomes complexs with a diameter lower than 100 ⁇ m, preferably lower than 50 ⁇ m, is disclosed.
  • said combination has a lubricating, moisturizing, antioxidative and photoprotective effect and it is particularly suitable for the protection and the treatment of eye degeneration caused by oxidative stresses, such as the exposure to light radiations or laser bean during refractive surgery, it is also suitable for the prevention and the treatment of cataract.
  • composition comprising superoxide dismutase and carboxy methyl 1,3-glucan CGM.
  • a further object of the present invention is a composition comprising superoxide dismutase and a sodium carboxy methyl 1,3-glucan/liposome complex as described in PCT/IT2006/000543, herein included by reference.
  • superoxide dismutase is in a concentration from 0,001% to 2% and CGM is in a concentration from 0,01 % to 5 %.
  • the composition, object of the present invention is used for the preparation of a medicament for the treatment and the prevention of corneal epithelium degeneration due to aging and oxidative stress caused by photoexposure.
  • Said medicament is preferably formulated as a collyrium.
  • the person with ordinary skills in the pharmaceutical field can appropriately add pharmaceutically acceptable adjuvants, carriers and excipients to be used in the preparation of collyrium.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composition comprising superoxide dismutase and carboxy methyl beta 1-3 glucan for the prevention of the degeneration of the corneal epithelium due to aging and to oxidative stress.

Description

Composition comprising superoxide dismutase and carboxy methyl beta 1,3- glucan Description of the invention
The present invention refers to the pharmaceutical field and in particular to a composition comprising superoxide dismutase and carboxy methyl beta 1-3 glucan in the form of liposomes or phosphoglucan to be used in the ophthalmic field for preventing the corneal epithelium degeneration caused by aging and oxidative stress.
European patent N. 1 421 974 in the name of the same applicant, discloses the use of carboxy methyl beta 1-3 glucan (herein named CGM) in a pharmaceutical preparation for improving lubrication and hydration of the eye, for stimulating the regenerative processes and having an immunostimulating effect.
Usually, in the pharmaceutical preparations CGM is preferably in aqueous solution and more preferably in a concentration from 0,2 % to 2%.
In one embodiment, the pharmaceutical preparation for ophthalmic use comprises CGM 0,5%, N-hydroxymethyl glicinate 0,001%, sodium edetate 0,1% and isotonic solution pH 7,2.
The International patent application N. PCT/IT2006/000543, in the name of the same applicant, discloses a pharmaceutical preparation for ophthalmic use or for oral administration comprising sodium carboxymethyl-beta-1,3- glucan CGM inside liposomes or bound to the liposome membrane, able to improve the lubrication of the eye and to protect the eye from irritation. In the formulation, the complex between sodium CGM and liposomes is preferably in a concentration from 0,1% to 50%, more preferably from 0,1 % to 5%.
The same composition, for oral administration, exerting an immunostimulating effect on the body, is also described.
The same application discloses a cosmetic composition, comprising the same sodium CGM/liposomes complex, with a protective and regenerative effect on the skin.
Furthermore, a process for the preparation of the sodium CGM/liposomes complex by homogenization of a sodium CGM solution with a liposomes preparation or a mixture of water/glicerin/alcoho! followed by the filtration through a membrane with pores of 1-5 μm in order to obtain sodium
CGM/liposomes complexs with a diameter lower than 100 μm, preferably lower than 50 μm, is disclosed.
It is well known in the art that superoxide dismutase (hereinafter defined as
SOD) levels decrease with aging and in the presence of cataract (Scharf J et al., Ophthalmic Res. 1987;18:332-337; Scharf J et al., Arch Clin Exp
Ophthalmol, 1987;225:133-136).
It has been demonstrated that during cataract development, SOD becomes thermolabile and inactive (Ohrloff C et al., Mod Trends Aging Res
1986;147:365-371), the enzyme inactivation is caused by glycation of lysine
(Lys) residues in the molecule reaction centre (Takata I et al., Biochem
Biophys Res Commun. 1996;219:243-248.73). On the contrary, SOD expression prevents cataract formation (Lin D et al.,
Molecular Vision, 2005; 11:853-8) and protects the corneal endothelium from aging and oxidative stress (Behndig A et al., IOVS, 2001, 42-12).
There is a strong need to avoid degenerative processes due to oxidative stress and to prevent cataract formation which may dangerously compromise the eye functions.
It was proven that the combination between superoxide dismutase and carboxy methyl beta 1,3-glucan in liposomes exert a surprisingly synergic effect which is higher that the effect exerted by the single components alone.
In particular, said combination has a lubricating, moisturizing, antioxidative and photoprotective effect and it is particularly suitable for the protection and the treatment of eye degeneration caused by oxidative stresses, such as the exposure to light radiations or laser bean during refractive surgery, it is also suitable for the prevention and the treatment of cataract.
It is an object of the present invention a composition comprising superoxide dismutase and carboxy methyl 1,3-glucan CGM.
A further object of the present invention is a composition comprising superoxide dismutase and a sodium carboxy methyl 1,3-glucan/liposome complex as described in PCT/IT2006/000543, herein included by reference.
Preferably, superoxide dismutase is in a concentration from 0,001% to 2% and CGM is in a concentration from 0,01 % to 5 %. The composition, object of the present invention, is used for the preparation of a medicament for the treatment and the prevention of corneal epithelium degeneration due to aging and oxidative stress caused by photoexposure.
Said medicament is preferably formulated as a collyrium.
The person with ordinary skills in the pharmaceutical field can appropriately add pharmaceutically acceptable adjuvants, carriers and excipients to be used in the preparation of collyrium.
In a preferred embodiment the collyrium has the following composition:
Superoxide dismutase 0,001- 2%
CGM 0,01 - 5%
Edta disodium salt 0,05 - 1%
Microglicin-50 0,001- 0.5%
Copolymer PVA/MA 0,0005 - 1%
Sodium hydrate 0,0005 - 0.5%
Sodium Chloride 0,1 - 1%
Sodium phosphate monobasic 0,1 - 1%
Sodium phosphate dibasic 0,1- 2%
Demi water to 100

Claims

Claims
1. Composition comprising superoxide dismutase and carboxy methyl beta 1,3- glucan.
2. Composition according to claim 1 wherein carboxy methyl beta 1,3-glucan is in a complex with liposomes.
3. Composition according to claim 2 wherein carboxy methyl beta 1,3-glucan is in the form of a sodium (Na) salt.
4. Composition according to claim 1 wherein superoxide dismutase is in a concentration from 0,001% to 2%.
5. Composition according to any one of the claims from 1 to 3 wherein carboxy methyl beta 1,3-glucan is in a concentration from 0,01 % to 5 %.
6. Use of the composition of any one of the claims from 1 to 5 for the preparation of a medicament.
7. Use of the composition of any one of the claims from 1 to 5 for the preparation of a medicament for the prevention of the degeneration of the corneal epithelium due to aging and oxidative stress.
8. Formulation in the form of collyrium having the following composition: Superoxide Dismutase 0,001- 2%
Phosphoglucan 0,01 - 5%
Edta disodium salt 0,05 - 1%
Microglicin-50 0,001- 0.5%
Copolymer PVA/MA 0,0005 - 1%
Sodium hydrate 0,0005 - 0.5% Sodium Chloride 0,1 - 1%
Sodium phosphate monobasic 0,1 - 1%
Sodium phosphate dibasic 0,1- 2%
Water demi to 100
EP07866845A 2007-12-27 2007-12-27 Composition comprising superoxide dismutase and carboxv methyl beta-1,3 glucan Withdrawn EP2229180A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2007/000914 WO2009084044A1 (en) 2007-12-27 2007-12-27 Composition comprising superoxide dismutase and carboxv methyl beta-1,3 glucan

Publications (1)

Publication Number Publication Date
EP2229180A1 true EP2229180A1 (en) 2010-09-22

Family

ID=39731080

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07866845A Withdrawn EP2229180A1 (en) 2007-12-27 2007-12-27 Composition comprising superoxide dismutase and carboxv methyl beta-1,3 glucan

Country Status (3)

Country Link
EP (1) EP2229180A1 (en)
IL (1) IL206273A0 (en)
WO (1) WO2009084044A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1277707B1 (en) * 1995-12-22 1997-11-11 Chemedica Sa OPHTHALMIC FORMULATION BASED ON SODIUM HYALURONATE FOR USE IN OCULAR SURGERY
EP1047392A4 (en) * 1997-12-24 2004-10-06 Shaklee Corp Composition with high efficiency skin protection from damaging effects of ultraviolet light
US7011845B2 (en) * 2000-05-09 2006-03-14 Mcp Hahnemann University β-glucans encapsulated in liposomes
ES2276906T3 (en) * 2002-06-10 2007-07-01 D.M.G. Italia Srl OPHTHALMIC SOLUTION CONTAINING CARBOXI METRO BETA-1,3 GLUCANO.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009084044A1 *

Also Published As

Publication number Publication date
WO2009084044A1 (en) 2009-07-09
IL206273A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
JP2005104862A (en) Aged macular degeneration therapeutic agent
WO2020021481A1 (en) Compositions and methods for treating the eye
JP5167499B2 (en) Use of pirenoxine to protect corneal tissue in photokeratotomy
JP3362501B2 (en) Corneal disorder treatment
JP2024107298A (en) Compositions for treating the eye
JP2024109914A (en) Compositions for treating the eye
JP2005516017A (en) Pharmaceutical conjugates exhibiting improved pharmacokinetic properties
AU2022263530A1 (en) Compositions and methods for treating the eye
WO2009084044A1 (en) Composition comprising superoxide dismutase and carboxv methyl beta-1,3 glucan
JP2011144111A (en) Axial myopia-preventing or treating agent
RU2795913C2 (en) Compositions and methods for treating eye disorders
RU2792627C2 (en) Compositions and methods for treating eye disorders
EP3824877A1 (en) Compositions and methods for treating the eye
US11969451B2 (en) Compositions and methods for treating the eye
RU2793736C2 (en) Compositions and methods for eye treatment
US8916543B1 (en) Inhibitors of alpha-toxin
WO2022079664A1 (en) Benzalkonium chloride for use in treating conjunctivitis and/or covid-19
RU2171659C2 (en) Method for applying medication treatment of keratoconus
JP2005200411A (en) Lacrimal fluid layer stabilizing agent
WO2005058932A1 (en) Tear layer stabilizer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100705

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RTI1 Title (correction)

Free format text: COMPOSITION COMPRISING SUPEROXIDE DISMUTASE AND CARBOXY METHYL BETA-1,3 GLUCAN

17Q First examination report despatched

Effective date: 20130624

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140329